🔗 Share this article

While America undertakes unprecedented adjustments to its immunization schedules, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots in the global health crisis and has focused upon potential deaths following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Health officials had intended to unveil sweeping changes to the childhood vaccination calendar in December, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US at odds with a large portion of the international standard with insufficient data for improved outcomes. This reveal has been postponed until the new year.

Rather than Vinay Prasad, Høeg is listed to speak at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and biologics branches as Høeg and Prasad strengthen their influence at the agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending certain pediatric immunization guidelines in the US so as to align more like Denmark, a nation with universal health coverage and a citizenry about the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – usually the purview of Dr. Prasad, head of the FDA’s CBER – instead of medication approval.

Doubts Over Expertise

The appointee has no obvious experience in medication creation, regulation or management, which has been standard for former directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “grasp legal statutes and the science of drug development”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who ran the center have had.”

CDER has an enormous workload at the FDA, Woodcock pointed out.

“Many people just pays attention on the novel medication approvals, but the generic program clears a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and every single one need to be looked after,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial management component to the job, which oversees in excess of 5,000 employees. “It is a enormous leadership role, if you execute it properly,” Woodcock said.

Official Statement and Disputed Policies

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “concerns stem from incorrect assumptions”.

“Her resume aligns with the functions of her role,” the representative said, pointing to the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a contentious rapid medication authorization process that apparently worried her predecessors. “How are these medications being picked for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed rules of all drugs, except for shots.”

Established Past Work on Vaccines

Regarding vaccines, Høeg has a clearer, if concerning, history, critics have noted. She released a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed changing guidelines for novel immunizations and ending “unnecessary” vaccines, she said following the vote on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of excluding adolescent males from getting Covid vaccinations.

“She’s an all-around true believer who starts off with her beliefs and tailors the evidence to fit the data in a very deceptive, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|